Clinical experience of CAR T cell therapy in lymphomas

Best Pract Res Clin Haematol. 2021 Sep;34(3):101281. doi: 10.1016/j.beha.2021.101281. Epub 2021 Jun 26.


Non-Hodgkin lymphoma in relapse portends a poor prognosis due to resistance to cytotoxic chemotherapy and monoclonal antibodies. Chimeric Antigen receptor (CAR) T cell therapy has been tested in many lymphomas in the relapse refractory setting and has resulted in durable responses despite some peculiar side effects including cytokine release syndrome (CRS), neurological events (NE), prolonged cytopenias and hypogammaglobulinemia. This review summarizes the registration trials conducted in lymphomas. All products showed response rates that were far better than obtainable by salvage chemotherapy and most patients recovered from side effects including CRS and NEs. The impact of CAR T in the real world setting was discussed as well as how to approach the use of CAR T in special circumstances such as CNS involvement, management of post CAR relapses and outpatient therapy.

Keywords: Chimeric antigen receptor therapy; Cytokine release syndrome; Neurological events; Real world; Relapse refractory lymphoma.

Publication types

  • Review

MeSH terms

  • Antigens, CD19
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma*
  • Neoplasm Recurrence, Local
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Chimeric Antigen* / genetics


  • Antigens, CD19
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen